NYSE:TEVAPharmaceuticals
How Investors May Respond To Teva (TEVA) Advancing TEV ‘325 In Biologics For Inflammatory Diseases
Biolojic Design recently announced that TEV ‘325, a multibody targeting IL-13 and TSLP for TH2-driven inflammatory diseases, achieved a preclinical milestone in its collaboration with Teva, triggering milestone payments and confirming Teva’s exclusive global development and commercialization rights.
This milestone underscores Teva’s progress in innovative biologics, adding scientific and commercial depth to its inflammatory disease pipeline alongside its established generics and branded...